Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B7-H3-targeted UCAR-T cell injection
- Development stage
- Unknown
- Lead developer
- The Second Affiliated Hospital of Soochow University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Parenteral
01
Overview
B7-H3-targeted UCAR-T cell injection is an investigational universal chimeric antigen receptor T-cell (UCAR-T) therapy developed by the Second Affiliated Hospital of Soochow University for the treatment of advanced gliomas. The therapy targets B7-H3 (CD276), an immune checkpoint molecule that is highly expressed in various solid tumors, including high-grade gliomas, but has limited expression in normal tissues. As a universal CAR-T product, it is designed for allogeneic use, potentially allowing for off-the-shelf administration to patients without the need for patient-specific cell manufacturing. It is currently being evaluated in early-phase clinical trials to assess its safety, tolerability, and preliminary efficacy in patients with relapsed or refractory high-grade glioma.
- Other names
- B7-H3 UCAR-TB-7-H3 UCAR-TB 7-H3 UCAR-TB7-H3-targeted universal CAR-T cell injectionB-7-H3-targeted universal CAR-T cell injectionB 7-H3-targeted universal CAR-T cell injection
02
Targets
B7-H3
Beyond the preview
Go deeper on B7-H3-targeted UCAR-T cell injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B7-H3-targeted UCAR-T cell injection.